NCT01651039 · OUTCOME

Overall Response Rate for Len Refractory Patients

Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM) · Source last updated 2018-04-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: COUNT_OF_PARTICIPANTS
Unit: Participants
Interval / dispersion: Not reported
Time frame: up to 4 years

What was measured

The primary endpoint will be the best overall response rate (ORR)

Analysis population: Only Len Refractory Patients

Groups in this outcome

Panobinostat, Lenalidomide and Dexamethasone

All patients received oral panobinostat, lenalidomide and dexamethasone as per protocol

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Panobinostat, Lenalidomide and Dexamethasone	22

Reported measurements

Source class 1

Values in Participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Panobinostat, Lenalidomide and Dexamethasone	8	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
8

denoms

counts
group Id
OG000
value
22
units
Participants

description

The primary endpoint will be the best overall response rate (ORR)

groups

description
All patients received oral panobinostat, lenalidomide and dexamethasone as per protocol
id
OG000
title
Panobinostat, Lenalidomide and Dexamethasone

param Type

COUNT_OF_PARTICIPANTS

population Description

Only Len Refractory Patients

reporting Status

POSTED

time Frame

up to 4 years

title

Overall Response Rate for Len Refractory Patients

type

PRIMARY

unit Of Measure

Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice